Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
Kimberly Spooner,1–3 Thomas Hong,1,2 Wijeyanthy Wijeyakumar,1–3 Andrew A Chang1–3 1Sydney Retina Clinic & Day Surgery, 2Sydney Institute of Vision Science, Sydney, 3Save Sight Institute, Department of Ophthalmology, University of Sydney, Camperdown, NSW, Austra...
Guardado en:
Autores principales: | Spooner K, Hong T, Wijeyakumar W, Chang AA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d0231c68719f4667afef0f54a0b34221 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019) -
The burden of neovascular age-related macular degeneration: a patient’s perspective
por: Spooner KL, et al.
Publicado: (2018) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016) -
Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018) -
Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi S, et al.
Publicado: (2021)